FDA approves Rinvoq as first oral therapy for moderate to severe Crohn’s disease (Healio)

Key takeaways:

• Upadacitinib is the first approved oral product to treat moderately to severely active Crohn’s disease.
• Expanded upadacitinib use is approved for patients who are refractory to treatment with one or more TNF inhibitors.

The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.